Affiliations: [a] Department of Neurology, University Hospital of Zealand, Roskilde, Denmark
| [b] Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
| [c] Department of Neurology, Danish Dementia Research Centre (DDRC), Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
Correspondence:
[*]
Correspondence to: Michael Hén Forbord Fischer, Vestermarksvej 11, 4000, Roskilde, Denmark. Tel.: +45 24763367; E-mail: mihh@regionsjaelland.dk.
Abstract: Background:Magnitude-squared coherence (MSCOH) is an electroencephalography (EEG) measure of functional connectivity. MSCOH has been widely applied to investigate pathological changes in patients with Alzheimer’s disease (AD). However, significant heterogeneity exists between the studies using MSOCH. Objective:We systematically reviewed the literature on MSCOH changes in AD as compared to healthy controls to investigate the clinical utility of MSCOH as a marker of AD. Methods:We searched PubMed, Embase, and Scopus to identify studies reporting EEG MSCOH used in patients with AD. The identified studies were independently screened by two researchers and the data was extracted, which included cognitive scores, preprocessing steps, and changes in MSCOH across frequency bands. Results:A total of 35 studies investigating changes in MSCOH in patients with AD were included in the review. Alpha coherence was significantly decreased in patients with AD in 24 out of 34 studies. Differences in other frequency bands were less consistent. Some studies showed that MSCOH may serve as a diagnostic marker of AD. Conclusion:Reduced alpha MSCOH is present in patients with AD and MSCOH may serve as a diagnostic marker. However, studies validating MSCOH as a diagnostic marker are needed.
